ASCO Breast Cancer
Conference Coverage
Genomic signature predicts safety of omitting RT in early breast cancer
Conference Coverage
ACE inhibitor prevents trastuzumab-associated LVEF decline after anthracyclines in BC treatment
Conference Coverage
Pregnancy effect on chemotherapy does not affect maternal breast cancer outcomes
Conference Coverage
ASCO 2021: Breast cancer sessions not to miss
Conference Coverage
'Exciting': Olaparib benefit also in early BRCA+ breast cancer
Conference Coverage
IL-6 levels predict distant breast cancer recurrence
Conference Recap
Key Studies in Metastatic Breast Cancer From ASCO 2020
Key studies in metastatic breast cancer from ASCO 2020 focus on first-line checkpoint inhibition in TNBC; also, updated...
Conference Coverage
Germline testing in advanced cancer can lead to targeted treatment
In a study of nearly 12,000 cancer patients, 7%-9% of patients had targetable germline alterations.
Conference Coverage
Treating primary tumor doesn’t improve OS in stage IV breast cancer
Conference Coverage
Pyrotinib bests lapatinib in HER2+ metastatic breast cancer
Patients who received pyrotinib had longer progression-free survival but a higher rate of grade 3 diarrhea.
Conference Coverage
Expanding the role of PARP inhibitors in breast cancer